Welcome to our dedicated page for Ludwig Enter news (Ticker: LUDG), a resource for investors and traders seeking the latest updates and insights on Ludwig Enter stock.
Ludwig Enterprises, Inc. (LUDG) delivers cutting-edge solutions at the intersection of mRNA genomics and artificial intelligence. This news hub provides investors and healthcare professionals with essential updates on the company's non-invasive diagnostic innovations, strategic partnerships, and clinical research developments.
Access real-time updates on FDA submissions, intellectual property milestones, and Revealia™ cancer screening enhancements. Our curated news collection covers earnings announcements, preclinical study results, and AI algorithm advancements that power the company's proprietary inflammatory index.
Key focus areas include mRNA biomarker discoveries, machine learning model refinements, and collaborations with leading medical institutions. Track progress in early detection technologies for chronic inflammation-related diseases, including breast cancer and cardiovascular conditions.
Bookmark this page for streamlined access to Ludwig's regulatory filings, executive commentary, and peer-reviewed research findings. Subscribe to our alerts for immediate notifications about material developments in this dynamic biotechnology sector.
Ludwig Enterprises Inc. (OTC PINK:LUDG) is advancing its application to trade on the OTCQB Market, a significant step towards future listings on the NYSE or NASDAQ. This transition is poised to enhance investor visibility and access a broader capital pool, providing crucial liquidity. The OTCQB tier requires stringent financial disclosures and maintains higher trading standards than other OTC markets. The move aims to strengthen Ludwig's potential as an investment opportunity, promoting growth and transparency for shareholders.
Ludwig Enterprises (OTC PINK:LUDG) has received IRB approval for a clinical study on bladder cancer, specifically targeting urothelial carcinoma. The study will use mRNA technology to evaluate the efficacy of BCG immunotherapy and aim to establish a personalized 'L-genomic bladder cancer risk' score for patients. This innovative approach could enhance cancer detection and treatment planning, potentially improving survival rates. With bladder cancer being a significant public health issue, the study aims to provide valuable insights for effective patient management.
Ludwig Enterprises, Inc. (OTC PINK:LUDG) announced significant progress in its 2022 annual shareholder letter. Notable changes include the acquisition of mRNA genomic technology and the filing of a patent for the Precision Genomics MRNA Inflammatory Index. A new subsidiary, MyRNA for Life, Inc., was launched to market an antioxidant nutraceutical. Key achievements include onboarding to the SRAX Shareholder Platform, acquiring assets, and IPO preparations. These advancements aim to enhance early disease detection and offer substantial cost savings in healthcare.
Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced the acquisition of a nutraceutical formula from Xikoz, Inc., underlining their commitment to health innovation. The new product, MyRNA for Life, is scheduled for launch in Q1 2023 and focuses on modulating inflammatory conditions linked to chronic diseases such as cancer and diabetes. This acquisition aims to empower individuals in managing their health through nutrition while leveraging Ludwig's advanced genomics technology for early disease detection. The company is poised to impact the billion-dollar healthcare market significantly.
Ludwig Enterprises (OTC PINK: LUDG) is planning to up-list to NASDAQ following a form S-1 registration statement filing. The company aims for an IPO launch in Q1 2023, with $1 million bridge financing targeted, of which $500,000 has already been raised. The firm engaged Newlin Law Firm for the S-1 process, which includes a PCAOB audit. Additionally, Ludwig's subsidiary, Precision Genomics, has gained interest after a successful presentation at the LD Micro Conference. They focus on genetic biomarkers for chronic diseases.
Ludwig Enterprises (OTC PINK: LUDG) has announced significant advancements through its subsidiary, Precision Genomics, during a SEQUIRE Spotlight featuring Dr. Marvin S. Hausman M.D. Key developments include a recent patent filing for a diagnostic method targeting chronic inflammation, and an upcoming bladder cancer study. The company plans to file an S1 with the SEC to facilitate its uplisting to the NASDAQ. These efforts aim to enhance disease management and treatment options in the healthcare sector.
Ludwig Enterprises (OTC PINK:LUDG) announced a successful participation at the LD Micro Conference, showcasing its subsidiary, Precision Genomics. Dr. Marvin S. Hausman MD, recognized for his past successes in taking medical companies public, represented Precision Genomics and engaged in one-on-one meetings with major investment banks.
The company is preparing to file an S-1 with the SEC, aiming for a NASDAQ listing. Precision Genomics focuses on genomic testing to improve health outcomes, working on research related to Long Covid and other diseases.
Precision Genomics, a division of Ludwig Enterprises (OTC PINK:LUDG), reveals its proprietary mRNA technology aimed at diagnosing and treating Long Covid. This new approach utilizes a 48-gene mRNA microarray to provide a personalized inflammatory profile, potentially offering greater diagnostic accuracy compared to traditional blood tests. The company is preparing formal clinical trials for this technology while planning to file an S-1 with the SEC to achieve a NASDAQ listing. The market potential for this innovative diagnostic tool is significant, possibly reaching billions.
Ludwig Enterprises (OTC PINK:LUDG) announced advancements in its mRNA Inflammatory Index, a genetic tool designed to diagnose and manage chronic inflammatory diseases like heart disease and cancer. The company recently filed a crucial patent and is partnering with the Genetic Institute of America to leverage advanced robotic systems for mRNA testing. The global biochip market is projected to reach USD 34.35 billion by 2030, driven by the increasing prevalence of chronic diseases. CEO Anne Blackstone expressed optimism about the transformative potential of this technology.
Ludwig Enterprises announced the filing of a patent for its innovative mRNA Inflammatory Index™, a technology aimed at improving diagnosis and management of inflammatory diseases such as heart disease, diabetes, and various cancers. This patent covers proprietary methods for measuring genetic inflammatory biomarkers, potentially allowing early detection and treatment modification. The company highlights the untapped market for this technology within the billion-dollar healthcare sector, suggesting significant cost savings and improved patient outcomes. Market competition remains limited, presenting a unique opportunity.
